Guardant Health (GH)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Guardant Health (GH)
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Key Insights
Critical company metrics and information
Share Price
$35.64Market Cap
$4.40 BillionTotal Outstanding Shares
123.56 Million SharesTotal Employees
1,779Dividend
No dividendIPO Date
October 4, 2018SIC Description
Services-medical LaboratoriesHomepage
https://www.guardanthealth.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $391.62 Million |
Net Cash Flow | $231.92 Million |
Net Cash Flow From Financing Activities, Continuing | $92.51 Million |
Net Cash Flow From Operating Activities | $-254.07 Million |
Net Cash Flow, Continuing | $230.05 Million |
Net Cash Flow From Operating Activities, Continuing | $-254.07 Million |
Net Cash Flow From Financing Activities | $92.51 Million |
Net Cash Flow From Investing Activities | $391.62 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Operating Expenses | $863.33 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Income Tax Expense/Benefit | $27,000.00 |
Benefits Costs and Expenses | $1.20 Billion |
Costs And Expenses | $1.21 Billion |
Net Income/Loss Available To Common Stockholders, Basic | $-512.41 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Diluted Earnings Per Share | $-4.28 |
Income/Loss From Continuing Operations Before Tax | $-512.38 Million |
Operating Income/Loss | $-515.14 Million |
Basic Average Shares | $124.60 Million |
Research and Development | $344.07 Million |
Revenues | $692.26 Million |
Income/Loss From Continuing Operations After Tax | $-512.41 Million |
Operating Expenses | $1.21 Billion |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss | $-512.41 Million |
Diluted Average Shares | $124.60 Million |
Basic Earnings Per Share | $-4.28 |
Net Income/Loss Attributable To Parent | $-512.41 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Equity Attributable To Parent | $-60.10 Million |
Current Liabilities | $197.34 Million |
Current Assets | $1.23 Billion |
Other Current Liabilities | $181.87 Million |
Accounts Payable | $15.47 Million |
Noncurrent Assets | $312.01 Million |
Liabilities | $1.60 Billion |
Fixed Assets | $125.17 Million |
Liabilities And Equity | $1.54 Billion |
Noncurrent Liabilities | $1.40 Billion |
Equity | $-60.10 Million |
Other Non-current Assets | $179.59 Million |
Intangible Assets | $7.25 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Assets | $1.54 Billion |
Inventory | $72.30 Million |
Other Current Assets | $1.15 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.